Lennham Pharmaceuticals, a clinical-stage start-up focused on the creative use of deuterium chemistry to improve the metabolic and pharmacological profile of existing compounds, today announced that the United States Patent & Trademark Office (USPTO) issued U.S. Patent No. 11,000,534 with an expiration date of December 2040. This patent broadly covers pharmaceutical compositions comprising deuterated forms of psilocybin. “Psilocybin has shown incredible promise in recent clinical studies as a potential treatment for major depressive disorder and other psychiatric diseases and disorders,” said Bradford C. Sippy, Founder and CEO of Lennham. “However, because psilocybin is a naturally occurring and extensively studied compound, it is unlikely that meaningful patent protection can be obtained on psilocybin or any products incorporating psilocybin. The issuance of this patent positions Lennham to have the most significant patent coverage for any psilocybin-based product in development. We intend to rapidly advance our differentiated product through the 505(b)(2) approval pathway by leveraging the existing known data on psilocybin.” The issued patent is entitled “Deuterated Derivatives of Psilocybin and Uses Thereof”. The issued claims are directed to pharmaceutical compositions comprising two forms of deuterium-enriched psilocybin.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!